| Methods |
Washout phase; 4‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 95‐114 mm Hg, with a difference of 10 mm Hg or less at last 2 consecutive visits of run‐in; subjects with DBP =/> 110 mm Hg could be included directly following minimum of 7 days single‐blind placebo; 8‐week double‐blind treatment |
| Participants |
Moexipril 7.5 mg: n=50(21 males,29 females); mean age=70.4 years; baseline sitting SBP=173 mm Hg, DBP=102 mm Hg, HR=76.7 bpm;
Moexipril 15 mg: n=53(31 males,22 females); mean age=69.2 years; baseline sitting SBP=169 mm Hg, DBP=102 mm Hg, HR=73.9 bpm;
Placebo: n=48(33 males,15 females); mean age=70.7 years; baseline sitting SBP=172 mm Hg, DBP=103 mm Hg, HR=72.7 bpm |
| Interventions |
Moexipril 7.5 mg once daily;
Moexipril 15 mg once daily;
Placebo |
| Outcomes |
Adjusted mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
Placebo‐corrected adjusted change from baseline in peak sitting DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SD of change reported, endpoint SBP not reported, endpoint DBP reported, endpoint SD not reported; change in trough BP data from Table 2, p. 261; placebo‐corrected change in peak DBP data from Table 4, p. 262; endpoint BP data used instead of weighted mean of BP change for 3 measurements (at weeks 4,6,8) because N values not reported for weeks 4 and 6; Jadad score=3; funding source= Schwarz Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
